Colombia Organica currently holds 3 licenses which include: production of cannabis derivatives, cultivation of psychoactive cannabis, and cultivation of non-psychoactive cannabis.
| VANCOUVER, British Columbia, March 20, 2019 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (CSE: MYM.CN) (MYM.CN) (“MYM” or “The Company”) is pleased to announce that it has increased its stake in Colombia Organica to 80%. Colombia Organica currently holds 3 licenses which include: production of cannabis derivatives, cultivation of psychoactive cannabis, and cultivation of non-psychoactive cannabis. Licenses include the capacity to export. Colombia Organica has submitted an application to certify cannabis seeds for commercialization. In addition, it holds a lease for a 36-acre property located 44 kms from Medellin. The region’s climate is conducive for growing cannabis with an average temperature of 16-18 °C, and an elevation of 2,475 meters above sea-level. They have secured an option to buy the property. MYM and Colombia Organica are building a production facility near Medellin, Colombia for the cultivation and processing of cannabis and cannabis products. Currently, Colombia Organica is developing and registering seed strains with the Colombian Agricultural Institute. MYM will acquire eighty 80% of Colombia Organica from its existing shareholders for consideration of cash, equity and loans to the company for a total package of up to $2.26 million. MYM will employ Colombia Organica principals Daniel Alonso and Gabriel Ramirez as Territory Managers for South American operations. “After further review we’ve decided to increase our stake in Colombia Organica under much more favourable terms”, said Howard Steinberg, CEO of MYM. “Colombia presents an exciting opportunity for MYM to expand its cultivation operations into South America, bringing with it increased value to our shareholders. The addition of Daniel and Gabriel to our team will provide the company with boots on the ground for all current and future projects in South America”. The Investment Agreement is subject to all required approvals and MYM’s due diligence. About Colombia Organica Colombia Organica is a Colombian company with expertise in the manufacture of pharmaceutical products, medicinal chemical substances and botanical products. Colombia Organica currently holds 3 licenses which include: production of THC cannabis derivatives, cultivation of psychoactive cannabis, and cultivation of non-psychoactive cannabis, including exportation. Colombia Organica has selected for production high quality plants which are suited to the unique high altitude, equatorial regions of Antioquia, Colombia. About MYM Nutraceuticals Inc. MYM Nutraceuticals Inc. is an innovative company focused on the global growth of cannabis and hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY). Keep up to date with MYM on our social media channels: Twitter: @mymnutra Facebook: @mymnutra Instagram: @mymnutra This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available. ON BEHALF OF THE BOARD Howard Steinberg, CEO Investor Relations
SOURCE MYM Nutraceuticals Inc. |
Company Codes: CNSX:MYM, Frankfurt:0MY, OTC-BB:MYMMF, Munich:0MY, OTC-PINK:MYMMF, OtherOTC:MYMMF, Stuttgart:0MY |
View original content: